On September 27, 2020, the Fifth China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the "Venture Investment Conference") was held in Suzhou Industrial Park. This conference focused on current hot topics and deeply focused on industrial policies in the post-epidemic era and global pharmaceutical research and development. Trends and investment and financing trends, comprehensively discuss global pharmaceutical innovation development trends, and discuss new developments in biomedical investment cooperation. Chen Deming, former Minister of Commerce and Chairman of China Association of Enterprises with Foreign Investment, Shang Fulin, Director of the Economic Committee of the National Committee of the Chinese People’s Political Consultative Conference and former Chairman of the China Banking Regulatory Commission, Bi Jingquan, Deputy Director of the Economic Committee of the National Committee of the Chinese People’s Political Consultative Conference, former Party Secretary and Deputy Director of the State Administration for Market Regulation, etc. Leaders of national ministries and commissions, as well as many domestic and foreign authoritative scientists, well-known entrepreneurs, and financial investment professionals were invited to attend.

　　President Chen Deming delivered a speech at the opening ceremony, fully affirming the important value of foreign pharmaceutical companies in China's pharmaceutical innovation and investment field and achieving the goal of a healthy China. Cao Hongying, executive vice president of China Association of Enterprises with Foreign Investment, and Kang Wei, executive president of RDPAC, were invited Attend the opening ceremony of the conference. Conway shared views on the topic of "Global Pharmaceutical Innovation and Development Trends" and called for continued strengthening of cooperation between multinational pharmaceutical companies and local pharmaceutical companies to promote the innovative development of China's pharmaceutical industry. During the conference, the China Pharmaceutical Promotion Association and the China Association of Enterprises with Foreign Investment also jointly released the research results of the "Research on China's Most Valuable Biomedical Innovation City" project.

　　Foreign pharmaceutical companies are leaders in innovation and quality

　　In his opening speech, President Chen Deming first fully affirmed the value of foreign pharmaceutical companies in promoting the innovation and development of China's pharmaceutical industry. He pointed out that foreign pharmaceutical companies in China are also Chinese companies in legal terms, and they have gathered international technology and capital. Combined with advanced management experience and outstanding local talents in China, it has strong global competitiveness. "Foreign pharmaceutical companies are a member of the big family of Chinese pharmaceutical companies, and they will be duty-bound to participate in China's pharmaceutical innovation and investment construction. From a practical point of view, the products and services of foreign pharmaceutical companies generally have a high level of research and development, strict quality control, and efficacy. Well, it is one of the representatives and leaders of pharmaceutical innovation and investment. Therefore, Chinese foreign pharmaceutical companies are not outsiders of China's economic construction, and will actively integrate into the Chinese economy and actively serve China's public health."

　　"In the context of the global fight against the epidemic this year, the Chinese government has included biomedicine in China’s pillar industries for the first time, which has comprehensively improved the innovation and development capabilities of the biomedical industry. Foreign-funded pharmaceutical companies are willing to do their best for China’s biomedical innovation and hope to Continue to receive the support of the government, industry and experts, unite and join hands with domestic and foreign counterparts, cooperate in research and development, and continue to contribute to the health of the Chinese people." President Chen Deming pointed out that RDPAC has united 42 top multinational pharmaceutical companies in the world. By providing high-quality and innovative medical and health products and services, member companies support China to establish a sustainable medical and health system, promote the implementation of a healthy China strategy, promote the creation of a new ecological system of pharmaceutical innovation, and continuously improve the quality of life of residents. In the past two years, RDPAC member companies have introduced more than 100 innovative drugs to the Chinese market, accounting for 80% of all innovative drugs on the Chinese market during the same period. He emphasized that the new crown epidemic is still raging around the world. Mankind can only win by relying on the advancement of science and technology, effective drugs and long-lasting vaccines, but the new crown virus is by no means the last stubborn disease of human health, and medical innovation and investment can never stop. .

　　Multinational pharmaceutical companies increase cooperation with local companies to create high-quality innovations that benefit patients in China and the world

The theme discussion session of the opening ceremony of the Venture Capital Conference, Song Ruilin, Executive Chairman of China Pharmaceutical Promotion Association, Jiang Jiandong, Director of the Institute of Medicine of the Academy of Medical Sciences, Kang Wei, Executive President of RDPAC, He Ruyi, former Chief Scientist of CFDA Drug Evaluation Center, and Li Ning, CEO of Junshi Bio The "Global Pharmaceutical Innovation Development Trend" was discussed, emphasizing that encouraging innovative drugs is the development trend of global medicine. Unsatisfied clinical needs and health challenges such as rare diseases and infectious diseases are the value of continuous breakthroughs in pharmaceutical innovation.

　　"Global cooperation is the path to breakthroughs in pharmaceutical innovation. China's pharmaceutical innovation has entered the second echelon in the world. In the post-epidemic era, innovation and cooperation will become the two main keywords of the biomedical industry trend." RDPAC CEO Kang Wei shared in the topic discussion China emphasized, "It usually takes ten years to develop a new drug, but the sudden crisis of the new crown epidemic has made us realize that to meet the urgent and unmet clinical needs of mankind, we must rely on international cooperation to find solutions. In the COVID-19 pandemic, China announced the complete genetic sequence of the new coronavirus only 10 days after the first case report was discovered. Multinational companies and local Chinese companies immediately carried out unprecedented and extensive cooperation in the research and development of relevant testing reagents, drugs and vaccines. Rapid layout in other fields."

　　Conway pointed out that the current trend of cooperation and integration between multinational pharmaceutical companies and local innovative pharmaceutical companies is becoming stronger, which is reflected in the active license in and license out of my country’s pharmaceutical industry, and the continuous strengthening and deepening of drug R&D and commercialization cooperation. More and more multinational pharmaceutical companies are launching cooperation with local innovative pharmaceutical companies. 　　Multinational pharmaceutical companies and local companies share the same vision, that is, they hope that China will become a strong country in pharmaceutical innovation and an open platform for global biopharmaceutical innovation. Multinational pharmaceutical companies and local pharmaceutical companies are highly complementary in pharmaceutical innovation. Both parties should continue to strengthen in the future. The cohesion and cohesion of cooperation will work together to achieve the goal of "Healthy China 2030". Take this conference as an example, from more than a dozen RDPAC member companies including AstraZeneca, Boehringer Ingelheim, Eisai, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Servier, Xian Janssen, etc. Employees attended the conference and participated in discussions on the innovation and development of Chinese medicine in the post-epidemic era.

　　Kangwei also called for our medical insurance to pay more attention to valuable medical innovations in order to better allow medical innovation to benefit Chinese patients and increase the availability of innovative drugs. She pointed out that data shows that innovative drugs account for less than 10% of my country's medical insurance investment, while some developed countries account for 50%-60%. "RDPAC conducted research and calculations on the medical insurance fund, and found that in the past three batches of four purchases, 50 billion yuan can be saved. According to the spillover effect, it can probably affect 100 billion yuan. The freed part should be more invested in valuable innovation. "In medicine." She also said that according to the "Opinions on Deepening the Reform of the Medical Security System" issued by the State Council in March this year, by 2030, it will be fully completed with basic medical insurance as the main body, medical assistance as the foundation, and supplementary medical insurance and commercial insurance. Health insurance, charitable donations, and mutual medical assistance will develop a medical security system that will become the direction of future medical insurance reforms. The realization of this goal still requires the joint efforts of the entire industry.

　　Improve China's pharmaceutical innovation ecosystem and jointly contribute to a healthy China

　　In the post-epidemic era, China's biomedical industry has a large number of unmet needs and emerging excellent innovative technologies that will continue to drive the development of the industry, and "innovation" has become an industry keyword. Since 2015, RDPAC has jointly released a series of reports on the pharmaceutical innovation ecosystem in conjunction with a number of industry associations, discussing innovative solutions from the perspectives of concepts, policy mechanisms and capabilities, and continuing to provide advice and suggestions for the government and related institutions. . In order to further promote the high-quality development of my country's pharmaceutical innovation, improve the investment environment, avoid duplication of construction, and improve the efficiency of resource allocation, in May 2020, the pharmaceutical innovation city research project was officially launched. The research project is composed of RDPAC and the China Pharmaceutical Promotion Association. The representative medical innovation social organizations in China evaluate the innovation ecology and strength of my country's existing medical innovation cities from a third-party perspective, which will have an important impact on promoting the improvement of my country's medical innovation ecosystem, attracting talents, and investment.

　　On the afternoon of September 27, the Pharmaceutical Innovation City Development Forum and the "China's Most Valuable Biomedical Innovation City Research" project results release conference was held during the Fifth China Pharmaceutical Innovation and Investment Conference. The former Minister of the Ministry of Commerce, Chinese foreign-invested enterprises Association President Chen Deming, Deputy Director of the Economic Committee of the National Committee of the Chinese People’s Political Consultative Conference, former Party Secretary and Deputy Director of the State Administration for Market Regulation, Bi Jingquan, President of China Pharmaceutical Promotion Association, Chairman and CEO of Simcere Pharmaceuticals Ren Jinsheng, Executive Chairman of China Pharmaceutical Promotion Association Song Ruilin, Cao Hongying, Executive Vice President of the China Association of Enterprises with Foreign Investment, and Kang Wei, Executive President of RDPAC, jointly announced the results of the "China Biomedical Innovation City Research". President Chen Deming pointed out at the meeting that the evaluation of medical innovation cities should be objectively evaluated from six dimensions: city construction, policy guarantees, R&D resources, innovation systems, financing capabilities, and enterprise development. The local government needs to understand the development trend of the world's biomedicine and the development trend of corporate planning, and actively carry out "going out" and "bringing in". The conference also held a licensing ceremony for leading cities in the Pharmaceutical Innovation Index. Representatives from ten outstanding cities including Shanghai, Beijing, Guangzhou, Suzhou, Hangzhou, Shenzhen, Tianjin, Nanjing, Chengdu and Wuhan attended the event and listened to some of them. Urban pharmaceutical innovation and development experience shared by outstanding city representatives.

　　Venture Capital Conference has been successfully held five times since 2016. It is an annual pharmaceutical investment event that has attracted much attention in the Asia-Pacific region and has been highly recognized and widely praised by the pharmaceutical and investment communities. This year's Venture Capital Conference continues to implement the purpose of "promoting the integration of domestic and foreign social capital and pharmaceutical innovation, and improving the innovation capability of my country's pharmaceutical industry"; in-depth discussions on the development direction of China's pharmaceutical innovation and investment and financing in the post-epidemic era, showing the world China's pharmaceutical innovation The strong driving force in terms of advancement; to build a high-end dialogue and cooperation platform for efficient communication and matching precision for domestic and foreign pharmaceutical innovation projects, scientists, and investors.